江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会 | 《关于使用剩余超募资金永久补充流动资金的议案》 9 | | --- | 江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会须知 会议资料 二〇二五年七月 1 为了保证股东在本次股东大会依法行使职权，确保股东大会的正常秩序和 议事效率，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）、《江苏亚虹医药科技股份有限公司股东大会议事规则》等有关规 定，江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）特制 定本次股东大会会议须知： 一、为确认出席大会的股东及股东代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请 出席大会的股东或股东代理人或其他出席者提前 30 分钟到达会场签到确认参会 资格。在会议主持人宣布现场出席会议的股东和股东代理人人数及所持有的表 决权数量之前，会议登记应当终止。会议登记终止后进场的股东无权 ...

Core Viewpoint - On July 14, the Shanghai Composite Index rose by 0.27%, with institutional investors appearing on the trading lists of 35 stocks, net buying 19 and net selling 16 [1] Institutional Trading Summary - Institutional special seats net bought the most in Xiangyang Bearing, which closed at the daily limit with a turnover rate of 27.67% and a transaction amount of 2.076 billion yuan, net buying 110.74 million yuan [2] - San Chuan Wisdom closed up 15.27% with a turnover rate of 32.50%, net buying 75.27 million yuan, but had a net outflow of 35.2 million yuan [2] - Zhongke Magnetic Industry closed down 5.10% with a turnover rate of 45.77%, net buying 53.99 million yuan, but had a net outflow of 49.77 million yuan [2] Market Performance - The average increase of stocks with institutional net purchases was 2.36%, outperforming the Shanghai Composite Index [3] - Stocks like Changrong Co. and Xinling Electric showed strong performance, closing at the daily limit [3] - Historical data indicates a 52.06% probability of stocks with institutional net purchases rising the next day, and a 39.70% probability of rising in the following three days [3] Earnings Forecasts - Among the stocks with institutional net purchases, four have released half-year earnings forecasts, with Yuhua Development expected to have a net profit of 200 million yuan, a year-on-year increase of 708% [3] Net Selling Summary - The stock with the highest net selling by institutions was Siyuan Electric, with a net selling amount of 162.84 million yuan, while also seeing a net inflow of 98.77 million yuan [3] - Dazhihui was noted for a net selling of 120.24 million yuan, with a significant net outflow of 433 million yuan [4] Deep and Shanghai Stock Connect - On July 14, 15 stocks on the trading list had appearances from the Deep and Shanghai Stock Connect, with Siyuan Electric and Zhongke Jincai seeing net purchases of 139 million yuan and 113 million yuan respectively [7][8] - Stocks like Hengbao Co. and Greenland Holdings experienced significant net selling amounts of 193 million yuan and 79.38 million yuan respectively [8]

Market Overview - The Sci-Tech Innovation Board (STAR Market) index decreased by 0.21%, closing at 992.39 points, with a total trading volume of 2.875 billion shares and a turnover of 95.999 billion yuan, resulting in an average turnover rate of 1.61% [1] - Among the tradable stocks on the STAR Market, 358 stocks closed higher, with 6 stocks hitting the daily limit, while 219 stocks closed lower [1] Stock Performance - The highest turnover rate was recorded by Yitang Co., Ltd., a newly listed stock, which saw a decline of 1.86% and a turnover rate of 19.71%, with a daily transaction amount of 820 million yuan and a net outflow of 141 million yuan in main funds [1] - Other notable stocks with high turnover rates included Borui Data, which increased by 7.23% with a turnover rate of 18.73%, and Jin Chengzi, Zhongyan Co., and Saifen Technology, with turnover rates of 15.34%, 15.10%, and 14.80% respectively [1] High Turnover Stocks - Among stocks with a turnover rate exceeding 5%, 43 stocks increased in value today, with the highest gains from Zhijiang Biology (20.00%), Nanxin Pharmaceutical (18.16%), and Yanhong Pharmaceutical (17.32%) [2] - The pharmaceutical and biological sector had the most stocks with high turnover rates, totaling 20, followed by the computer and power equipment sectors with 10 and 6 stocks respectively [2] Fund Flow Analysis - In terms of fund flow, 32 stocks with high turnover rates experienced net inflows, with Zhijiang Biology, Yanhong Pharmaceutical, and Nanxin Pharmaceutical receiving the most significant net inflows of 100 million yuan, 82.6559 million yuan, and 31.76 million yuan respectively [2] - Conversely, Yitang Co., Ltd., Dingtong Technology, and Shijia Photon saw the largest net outflows, amounting to 141 million yuan, 89.163 million yuan, and 76.5522 million yuan respectively [2] Leverage Fund Movements - Recent data indicates that 37 stocks with high turnover rates received net purchases from leveraged funds, with Yitang Co., Ltd., Rongchang Biology, and Dingtong Technology seeing significant increases in financing balances of 260 million yuan, 80.9046 million yuan, and 79.4712 million yuan respectively [3] - Stocks with decreased financing balances included Youfang Technology, Yingshi Innovation, and Guangda Special Materials, with reductions of 142 million yuan, 82 million yuan, and 49.5677 million yuan respectively [3] Notable Stocks on July 14 - A list of notable stocks with high turnover rates includes: - Yitang Co., Ltd. (688729): Closing price 20.55, daily change -1.86%, turnover rate 19.71%, net outflow -140.50 million yuan [4] - Borui Data (688229): Closing price 64.55, daily change 7.23%, turnover rate 18.73%, net inflow 21.51 million yuan [4] - Jin Chengzi (688291): Closing price 35.28, daily change 1.50%, turnover rate 15.34%, net inflow 3.69 million yuan [4] - Zhongyan Co. (688716): Closing price 37.16, daily change 9.01%, turnover rate 15.10%, net inflow 24.58 million yuan [4] - Saifen Technology (688758): Closing price 17.54, daily change 3.91%, turnover rate 14.80%, net inflow 10.26 million yuan [4]

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]

Core Viewpoint - On July 7, a total of 30 listed companies had their restricted shares unlocked, with a total market value of approximately 15.657 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Xinda (000701) had 4.5378 million shares unlocked under equity incentive restrictions - Qianjiang Motorcycle (000913) had 117,500 shares unlocked under equity incentive restrictions - Shenhuo Co. (000933) had 5.1992 million shares unlocked under equity incentive restrictions - Xiamen Xiangyu (600057) had 28.3365 million shares unlocked under equity incentive restrictions - Inner Mongolia First Machinery (600967) had 20,630 shares unlocked under equity incentive restrictions - Bowei Alloys (601137) had 720,000 shares unlocked under equity incentive restrictions - Kebo Da (603786) had 1.5424 million shares unlocked under equity incentive restrictions - Jianke Co. (301115) had 90,000 shares unlocked under equity incentive restrictions - Jinhai Biological (002688) had 6.411 million shares unlocked under equity incentive restrictions - Tiantian Technology (300587) had 2.1044 million shares unlocked under equity incentive restrictions - Shengbang Co. (301233) had 994,200 shares unlocked under pre-issue restrictions - Zhonglan Environmental (300854) had 797,500 shares unlocked under equity incentive restrictions - Bidetech (605298) had 1.23 million shares unlocked under equity incentive restrictions - Tian'ao Electronics (002935) had 1.8468 million shares unlocked under equity incentive restrictions - Zhongyi Technology (301208) had 510,000 shares unlocked under pre-issue restrictions - Dielian Technology (300679) had 28,710 shares unlocked under equity incentive restrictions - Xishanghai (605151) had 544,000 shares unlocked under equity incentive restrictions - Dingsheng New Materials (603876) had 324,000 shares unlocked under equity incentive restrictions - Keli Sensor (603662) had 118,800 shares unlocked under equity incentive restrictions - Keri Technology (002957) had 451,100 shares unlocked under equity incentive restrictions - Puri Eye Hospital (301239) had 78.8296 million shares unlocked under pre-issue restrictions - Wuzhou Medical (301234) had 49.572 million shares unlocked under pre-issue restrictions - Sanwei Tiandi (301159) had 30.4475 million shares with extended lock-up period unlocked - Hush Silicon Industry (688126) had 11.3603 million shares unlocked - Junshi Biosciences (688180) had 1.8452 million shares unlocked - Olin Bio (688319) had 224,700 shares unlocked - Guoxin Technology (688262) had 71.6493 million shares unlocked - Yahui Pharmaceutical (688176) had 129 million shares unlocked - Lingyun Optical (688400) had 224 million shares unlocked - Aobi Zhongguang (688322) had 34.0322 million shares unlocked [1]

Group 1 - The company, Jiangsu Yahon Pharmaceutical Technology Co., Ltd., is convening its first extraordinary general meeting of shareholders in 2025 on July 25, 2025 [1][4] - The voting method for the meeting will combine on-site voting and online voting through the Shanghai Stock Exchange network voting system [1][4] - The meeting will take place at the Wanxin Hotel, located at 551 Gaoke West Road, Pudong New District, Shanghai [1][4] Group 2 - Shareholders eligible to attend the meeting are those registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on July 21, 2025 [5][6] - The meeting will include non-cumulative voting proposals that have been approved by the company's board and supervisory board in previous meetings [3][4] - There are no related shareholders that need to abstain from voting on the proposals [3] Group 3 - The registration for the meeting requires specific documents depending on the type of shareholder, including identification and proof of shareholding [6][7] - The company has provided contact information for inquiries related to the meeting, including phone numbers and email addresses [7] - Attendees will be responsible for their own travel and accommodation expenses for the meeting [7]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688176 证券简称：亚虹医药 公告编号：2025-028 江苏亚虹医药科技股份有限公司 关于召开2025年第一次临时股东大会的通知 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 25 日10 点 00 分 召开地点：上海市浦东新区高科西路 551 号万信酒店一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 25 日 至2025 年 7 月 25 日 1 股东大会召开日期：2025年7月25日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-027 江苏亚虹医药科技股份有限公司 首次公开发行部分限售股上市流通公告 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 56,234,510股。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 12 月 1 日出具的《关于同意江苏亚虹医药科技股份有限公司首次公开发行股票注册的批 复》（证监许可[2021]3797 号），江苏亚虹医药科技股份有限公司（以下简称"公司"） 首次向社会公众公开发行人民币普通股（A 股）股票 110,000,000 股，并于 2022 年 1 月 7 日在上海证券交易所科创板上市，发行完成后总股本为 570,000,000 股， 其中有限售条件流通股 469,225,978 股，无限售条件流通股 100,774,022 股。 本次上市流通的限售股为公司首次公开发行前部分限售股，涉及的限售股股 东数量为 ...

一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 12 月 1 日出具的《关于同意江苏亚虹医药科技股份有限公司首次公开发行股票注册的 批复》（证监许可[2021]3797 号），公司首次向社会公众公开发行人民币普通股（A 股）股票 110,000,000 股，并于 2022 年 1 月 7 日在上海证券交易所科创板上市， 发行完成后总股本为 570,000,000 股，其中有限售条件流通股 469,225,978 股，无 限售条件流通股 100,774,022 股。 本次上市流通的限售股为公司首次公开发行前部分限售股，涉及的限售股股 东数量为 3 名，对应的股份数量为 56,234,510 股，占公司股本总数的 9.87%。上 述股份原锁定期为自公司首次公开发行上市之日起 36 个月，基于对公司未来发 展前景的信心及投资价值的认可，自愿延长前述锁定期 6 个月至 2025 年 7 月 6 日。现锁定期即将届满，将于 2025 年 7 月 7 日起上市流通。 二、本次上市流通的限售股形成后至今股本数量变化情况 本次上市流通的限售股属于公司首次公开发行前限售股，自 ...

中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 中信证券股份有限公司（以下简称"保荐人"）作为江苏亚虹医药科技股份 有限公司（以下简称"公司"）首次公开发行股票并上市持续督导保荐人，根据 《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上 市公司募集资金监管规则》及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规的有关规定，对公司使用剩余超募资金永久补充 流动资金事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏亚虹医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕3797 号）同意注册，公司向社会 公开发行人民币普通股 11,000 万股，每股面值人民币 1 元，每股发行价为人民 币 22.98 元，募集资金总额为人民币 252,780.00 万元，扣除发行费用（不含增值 税）人民币 14,720.78 万元，实际募集资金净额为人民币 238,059.22 万元。以上 募集资金到位情况已经立信会计师事务所（特殊普通合伙）审验并出具了《验资 报告》（信会计师报字[2021]第 ZA1599 ...